Design Therapeutics, Inc.
DSGNNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $655.06M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $5.28$17.25
- Volume (live)
- -
- Avg. volume (3M)
- 708.85K
Design Therapeutics (DSGN) Stock Price & Financial Analysis
Design Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $10.16 - $10.50 |
|---|---|
| 52-Week High | $17.25 |
| 52-Week Low | $5.28 |
| Open | $10.46 |
| Volume (last close) | 854.55K |
| Average Volume (3M) | 708.85K |
| 50-Day MA | $13.62 |
|---|---|
| 200-Day MA | $12.09 |
| 1-Year Change | +82.58% |
| Market Cap | 655.06M |
|---|---|
| Shares Outstanding | 62.51M |
| Price to Book (P/B) | 3.25 |
| EV/EBITDA | -8.67 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Design Therapeutics at a Glance
As of the Oct 16, 2026 close, Design Therapeutics (DSGN) has a market capitalization of $655.06M.
As of its latest reported balance sheet, it holds $12.91M in cash and securities against $2.03M of debt, a net cash position of $10.88M.
Design Therapeutics does not currently pay a dividend.
The share price is up 82.6% over the past year. At $10.31 (the Oct 16, 2026 close) it sits within its 52-week range of $5.28 to $17.25, below its 200-day moving average of $12.09.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $27.13, 163.1% above the Oct 16, 2026 close.
Frequently Asked Questions About Design Therapeutics
What is the current stock price for DSGN?
As of the Oct 16, 2026 close, DSGN stock trades at $10.31. The 52-week range is $5.28–$17.25, with a day range of $10.16–$10.50.
What is the P/E ratio for DSGN?
The P/E ratio (Price-to-Earnings) for DSGN is shown in the Key Statistics section. This valuation metric helps compare Design Therapeutics, Inc. to industry peers.
Does DSGN pay dividends?
Design Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for DSGN?
Based on ratings from 4 professional analysts over the last 90 days, the consensus for DSGN is Buy. The average 12-month price target is $27.13, a 163.1% upside from the Oct 16, 2026 close of $10.31.
What is the market cap of DSGN?
As of the Oct 16, 2026 close, Design Therapeutics's market capitalization is $644.4M, classifying it as a small-cap company. Design Therapeutics operates in the Healthcare sector within the Biotechnology industry.